Peroxisome proliferator-activated receptor-γ agonist pioglitazone suppresses experimental autoimmune uveitis

Experimental Eye Research

Volumn 116, Issue , 2013, Pages 291-297

  Okunuki, Yoko ^a   Usui, Yoshihiko ^a   Nakagawa, Hayate ^a   Tajima, Kazuki ^a   Matsuda, Ryusaku ^a   Ueda, Shunichiro ^a   Hattori, Takaaki ^a   Kezuka, Takeshi ^a   Goto, Hiroshi ^a  

^a TOKYO MEDICAL UNIVERSITY   (Japan)

Author keywords

Experimental autoimmune uveitis; Foxp3; Pioglitazone; Proliferator activated receptor gamma

Indexed keywords

INTERLEUKIN 10; INTERLEUKIN 12P70; INTERLEUKIN 17; INTERLEUKIN 6; INTERLEUKIN 9; INTERPHOTORECEPTOR RETINOID BINDING PROTEIN; L SELECTIN; MONOCYTE CHEMOTACTIC PROTEIN 1; PIOGLITAZONE; TRANSCRIPTION FACTOR FOXP3; TUMOR NECROSIS FACTOR ALPHA;

ADOPTIVE TRANSFER; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN SPECIFICITY; ANTIINFLAMMATORY ACTIVITY; ARTICLE; AUTOIMMUNE UVEITIS; AXILLARY LYMPH NODE; CD4+ T LYMPHOCYTE; CELL PROLIFERATION; CONTROLLED STUDY; CYTOKINE PRODUCTION; DISEASE SEVERITY; EFFECTOR CELL; FEMALE; FLOW CYTOMETRY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HISTOPATHOLOGY; IN VITRO STUDY; LYMPH NODE; MOUSE; NONHUMAN; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; TH17 CELL; UVEORETINITIS;

EXPERIMENTAL AUTOIMMUNE UVEITIS; FOXP3; PIOGLITAZONE; PROLIFERATOR-ACTIVATED RECEPTOR-GAMMA;

ANIMALS; AUTOIMMUNE DISEASES; DISEASE MODELS, ANIMAL; FEMALE; FLOW CYTOMETRY; HUMANS; HYPOGLYCEMIC AGENTS; IMMUNITY, INNATE; INFUSIONS, INTRAVENOUS; MICE; MICE, INBRED C57BL; PPAR GAMMA; T-LYMPHOCYTES, REGULATORY; THIAZOLIDINEDIONES; UVEITIS;

EID: 84886810327     PISSN: 00144835     EISSN: 10960007     Source Type: Journal    
DOI: 10.1016/j.exer.2013.09.017     Document Type: Article

References (47)

1. Accorinti M., Pirraglia M.P., Paroli M.P., Priori R., Conti F., Pivetti-Pezzi P. Infliximab treatment for ocular and extraocular manifestations of Behcet's disease. Jpn. J. Ophthalmol. 2007, 51:191-196.
2. Aoun P., Simpkins J.W., Agarwal N. Role of PPAR-gamma ligands in neuroprotection against glutamate-induced cytotoxicity in retinal ganglion cells. Invest. Ophthalmol. Vis. Sci. 2003, 44:2999-3004.
3. Arnold R., Konig W. Peroxisome-proliferator-activated receptor-gamma agonists inhibit the release of proinflammatory cytokines from RSV-infected epithelial cells. Virology 2006, 346:427-439.
4. Chan C.C., Caspi R.R., Ni M., Leake W.C., Wiggert B., Chader G.J., Nussenblatt R.B. Pathology of experimental autoimmune uveoretinitis in mice. J.Autoimmun. 1990, 3:247-255.
5. Chen Z., Ishibashi S., Perrey S., Osuga J., Gotoda T., Kitamine T., Tamura Y., Okazaki H., Yahagi N., Iizuka Y., Shionoiri F., Ohashi K., Harada K., Shimano H., Nagai R., Yamada N. Troglitazone inhibits atherosclerosis in apolipoprotein E-knockout mice: pleiotropic effects on CD36 expression and HDL. Arterioscler. Thromb. Vasc. Biol. 2001, 21:372-377.
6. Clark R.B., Bishop-Bailey D., Estrada-Hernandez T., Hla T., Puddington L., Padula S.J. The nuclear receptor PPAR gamma and immunoregulation: PPAR gamma mediates inhibition of helper T cell responses. J.Immunol. 2000, 164:1364-1371.
7. Cunard R., Eto Y., Muljadi J.T., Glass C.K., Kelly C.J., Ricote M. Repression of IFN-gamma expression by peroxisome proliferator-activated receptor gamma. J.Immunol. 2004, 172:7530-7536.
8. Daynes R.A., Jones D.C. Emerging roles of PPARs in inflammation and immunity. Nat. Rev. Immunol. 2002, 2:748-759.
9. Evereklioglu C. Current concepts in the etiology and treatment of Behcet disease. Surv. Ophthalmol. 2005, 50:297-350.
10. Greene M.E., Blumberg B., McBride O.W., Yi H.F., Kronquist K., Kwan K., Hsieh L., Greene G., Nimer S.D. Isolation of the human peroxisome proliferator activated receptor gamma cDNA: expression in hematopoietic cells and chromosomal mapping. Gene Expr. 1995, 4:281-299.
11. Harris S.G., Phipps R.P. The nuclear receptor PPAR gamma is expressed by mouse T lymphocytes and PPAR gamma agonists induce apoptosis. Eur. J. Immunol. 2001, 31:1098-1105.
12. Hotamisligil G.S. Inflammation and metabolic disorders. Nature 2006, 444:860-867.
13. Jackson S.M., Parhami F., Xi X.P., Berliner J.A., Hsueh W.A., Law R.E., Demer L.L. Peroxisome proliferator-activated receptor activators target human endothelial cells to inhibit leukocyte-endothelial cell interaction. Arterioscler. Thromb. Vasc. Biol. 1999, 19:2094-2104.
14. Jiang C., Ting A.T., Seed B. PPAR-gamma agonists inhibit production of monocyte inflammatory cytokines. Nature 1998, 391:82-86.
15. Kawahito Y., Kondo M., Tsubouchi Y., Hashiramoto A., Bishop-Bailey D., Inoue K., Kohno M., Yamada R., Hla T., Sano H. 15-deoxy-delta(12,14)-PGJ(2) induces synoviocyte apoptosis and suppresses adjuvant-induced arthritis in rats. J.Clin. Invest. 2000, 106:189-197.
16. Klotz L., Diehl L., Dani I., Neumann H., von Oppen N., Dolf A., Endl E., Klockgether T., Engelhardt B., Knolle P. Brain endothelial PPARgamma controls inflammation-induced CD4+ T cell adhesion and transmigration invitro. J.Neuroimmunol. 2007, 190:34-43.
17. Klotz L., Schmidt M., Giese T., Sastre M., Knolle P., Klockgether T., Heneka M.T. Proinflammatory stimulation and pioglitazone treatment regulate peroxisome proliferator-activated receptor gamma levels in peripheral blood mononuclear cells from healthy controls and multiple sclerosis patients. J.Immunol. 2005, 175:4948-4955.
18. Lemberger T., Braissant O., Juge-Aubry C., Keller H., Saladin R., Staels B., Auwerx J., Burger A.G., Meier C.A., Wahli W. PPAR tissue distribution and interactions with other hormone-signaling pathways. Ann. N. Y. Acad. Sci. 1996, 804:231-251.
19. Muranaka K., Yanagi Y., Tamaki Y., Usui T., Kubota N., Iriyama A., Terauchi Y., Kadowaki T., Araie M. Effects of peroxisome proliferator-activated receptor gamma and its ligand on blood-retinal barrier in a streptozotocin-induced diabetic model. Invest. Ophthalmol. Vis. Sci. 2006, 47:4547-4552.
20. Murata T., He S., Hangai M., Ishibashi T., Xi X.P., Kim S., Hsueh W.A., Ryan S.J., Law R.E., Hinton D.R. Peroxisome proliferator-activated receptor-gamma ligands inhibit choroidal neovascularization. Invest. Ophthalmol. Vis. Sci. 2000, 41:2309-2317.
21. Neve B.P., Fruchart J.C., Staels B. Role of the peroxisome proliferator-activated receptors (PPAR) in atherosclerosis. Biochem. Pharmacol. 2000, 60:1245-1250.
22. Niino M., Iwabuchi K., Kikuchi S., Ato M., Morohashi T., Ogata A., Tashiro K., Onoe K. Amelioration of experimental autoimmune encephalomyelitis in C57BL/6 mice by an agonist of peroxisome proliferator-activated receptor-gamma. J.Neuroimmunol. 2001, 116:40-48.
23. Odegaard J.I., Ricardo-Gonzalez R.R., Goforth M.H., Morel C.R., Subramanian V., Mukundan L., Red Eagle A., Vats D., Brombacher F., Ferrante A.W., Chawla A. Macrophage-specific PPARgamma controls alternative activation and improves insulin resistance. Nature 2007, 447:1116-1120.
24. Okada A.A. Immunomodulatory therapy for ocular inflammatory disease: a basic manual and review of the literature. Ocul. Immunol. Inflamm. 2005, 13:335-351.
25. Okunuki Y., Usui Y., Nagai N., Kezuka T., Ishida S., Takeuchi M., Goto H. Suppression of experimental autoimmune uveitis by angiotensin II type 1 receptor blocker telmisartan. Invest. Ophthalmol. Vis. Sci. 2009, 50:2255-2261.
26. Pasceri V., Wu H.D., Willerson J.T., Yeh E.T. Modulation of vascular inflammation invitro and invivo by peroxisome proliferator-activated receptor-gamma activators. Circulation 2000, 101:235-238.
27. Pershadsingh H.A., Sproul J.A., Benjamin E., Finnegan J., Amin N.M. Treatment of psoriasis with troglitazone therapy. Arch. Dermatol. 1998, 134:1304-1305.
28. Ricote M., Huang J., Fajas L., Li A., Welch J., Najib J., Witztum J.L., Auwerx J., Palinski W., Glass C.K. Expression of the peroxisome proliferator-activated receptor gamma (PPARgamma) in human atherosclerosis and regulation in macrophages by colony stimulating factors and oxidized low density lipoprotein. Proc. Natl. Acad. Sci. U. S. A. 1998, 95:7614-7619.
29. Ricote M., Li A.C., Willson T.M., Kelly C.J., Glass C.K. The peroxisome proliferator-activated receptor-gamma is a negative regulator of macrophage activation. Nature 1998, 391:79-82.
30. Ruggieri S., Frassanito M.A., Dammacco R., Guerriero S. T(reg) lymphocytes in autoimmune uveitis. Ocul. Immunol. Inflamm. 2012, 20:255-261.
31. Ryan E.H., Han D.P., Ramsay R.C., Cantrill H.L., Bennett S.R., Dev S., Williams D.F. Diabetic macular edema associated with glitazone use. Retina 2006, 26:562-570.
32. Sarayba M.A., Li L., Tungsiripat T., Liu N.H., Sweet P.M., Patel A.J., Osann K.E., Chittiboyina A., Benson S.C., Pershadsingh H.A., Chuck R.S. Inhibition of corneal neovascularization by a peroxisome proliferator-activated receptor-gamma ligand. Exp. Eye Res. 2005, 80:435-442.
33. Schmidt S., Moric E., Schmidt M., Sastre M., Feinstein D.L., Heneka M.T. Anti-inflammatory and antiproliferative actions of PPAR-gamma agonists on T lymphocytes derived from MS patients. J.Leukoc. Biol. 2004, 75:478-485.
34. Shahin D., Toraby E.E., Abdel-Malek H., Boshra V., Elsamanoudy A.Z., Shaheen D. Effect of peroxisome proliferator-activated receptor gamma agonist (pioglitazone) and methotrexate on disease activity in rheumatoid arthritis (experimental and clinical study). Clin. Med. Insights. Arthritis Musculoskelet. Disord. 2011, 4:1-10.
35. Shoelson S.E., Lee J., Goldfine A.B. Inflammation and insulin resistance. J.Clin. Invest. 2006, 116:1793-1801.
36. Su C.G., Wen X., Bailey S.T., Jiang W., Rangwala S.M., Keilbaugh S.A., Flanigan A., Murthy S., Lazar M.A., Wu G.D. Anovel therapy for colitis utilizing PPAR-gamma ligands to inhibit the epithelial inflammatory response. J.Clin. Invest. 1999, 104:383-389.
37. Sugita S., Horie S., Nakamura O., Maruyama K., Takase H., Usui Y., Takeuchi M., Ishidoh K., Koike M., Uchiyama Y., Peters C., Yamamoto Y., Mochizuki M. Acquisition of T regulatory function in cathepsin L-inhibited T cells by eye-derived CTLA-2alpha during inflammatory conditions. J.Immunol. 2009, 183:5013-5022.
38. Sugita S., Yamada Y., Kaneko S., Horie S., Mochizuki M. Induction of regulatory T cells by infliximab in Behcet's disease. Invest. Ophthalmol. Vis. Sci. 2011, 52:476-484.
39. Thieringer R., Fenyk-Melody J.E., Le Grand C.B., Shelton B.A., Detmers P.A., Somers E.P., Carbin L., Moller D.E., Wright S.D., Berger J. Activation of peroxisome proliferator-activated receptor gamma does not inhibit IL-6 or TNF-alpha responses of macrophages to lipopolysaccharide invitro or invivo. J.Immunol. 2000, 164:1046-1054.
40. Thurau S.R., Chan C.C., Nussenblatt R.B., Caspi R.R. Oral tolerance in a murine model of relapsing experimental autoimmune uveoretinitis (EAU): induction of protective tolerance in primed animals. Clin. Exp. Immunol. 1997, 109:370-376.
41. Usui Y., Akiba H., Takeuchi M., Kezuka T., Takeuchi A., Hattori T., Okunuki Y., Yamazaki T., Yagita H., Usui M., Okumura K. The role of the ICOS/B7RP-1 T cell costimulatory pathway in murine experimental autoimmune uveoretinitis. Eur. J. Immunol. 2006, 36:3071-3081.
42. Wang R.X., Yu C.R., Mahdi R.M., Egwuagu C.E. Novel IL27p28/IL12p40 cytokine suppressed experimental autoimmune uveitis (EAU) by inhibiting autoreactive Th1/Th17 cells and promoting expansion of regulatory T cells. J.Biol. Chem. 2012, 287:36012-36021.
43. Weisberg S.P., McCann D., Desai M., Rosenbaum M., Leibel R.L., Ferrante A.W. Obesity is associated with macrophage accumulation in adipose tissue. J.Clin. Invest. 2003, 112:1796-1808.
44. Xu H., Barnes G.T., Yang Q., Tan G., Yang D., Chou C.J., Sole J., Nichols A., Ross J.S., Tartaglia L.A., Chen H. Chronic inflammation in fat plays a crucial role in the development of obesity-related insulin resistance. J.Clin. Invest. 2003, 112:1821-1830.
45. Yoshimura T., Sonoda K.H., Miyazaki Y., Iwakura Y., Ishibashi T., Yoshimura A., Yoshida H. Differential roles for IFN-gamma and IL-17 in experimental autoimmune uveoretinitis. Int. Immunol. 2008, 20:209-214.
46. Young P.W., Buckle D.R., Cantello B.C., Chapman H., Clapham J.C., Coyle P.J., Haigh D., Hindley R.M., Holder J.C., Kallender H., Latter A.J., Lawrie K.W., Mossakowska D., Murphy G.J., Roxbee Cox L., Smith S.A. Identification of high-affinity binding sites for the insulin sensitizer rosiglitazone (BRL-49653) in rodent and human adipocytes using a radioiodinated ligand for peroxisomal proliferator-activated receptor gamma. J.Pharmacol. Exp. 1998, 284:751-759.
47. Zhang R., Qian J., Guo J., Yuan Y.F., Xue K. Suppression of experimental autoimmune uveoretinitis by anti-IL-17 antibody. Curr. Eye Res. 2009, 34:297-303.